Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Breast Neoplasms 45Carcinoma, Non-Small-Cell Lung 2Wilms Tumor 1Urinary Bladder Neoplasms 1Sarcoma, Synovial 1Rhabdomyosarcoma 1Recurrence 1Pleuropulmonary blastoma 1Patient Preference 1Pancreatic Neoplasms 1Neurofibrosarcoma 1Neuroblastoma 1Neoplasm Metastasis 1Multiple Myeloma 1Inflammatory Breast Neoplasms 1HER2 Positive Breast Cancer 1Genomic Instability 1Cholangiocarcinoma 1Breast Cancer Metastatic 1Advanced Unresectable or Metastatic Solid Malignancy 1

Interventions

Cyclophosphamide 67Dexamethasone 52Peripheral Blood Stem Cell Transplantation 37Lenalidomide 37Rituximab 35fludarabine phosphate 34Bortezomib 30Filgrastim 27Etoposide 27Cytarabine 25Carboplatin 25Busulfan 23Radiotherapy 22Melphalan 22Gemcitabine 22Cyclosporine 21pomalidomide 20fludarabine 20Whole-Body Irradiation 20Mycophenolic Acid 20Paclitaxel 19Methotrexate 18venetoclax 17Cisplatin 17pembrolizumab 16Calcium Dobesilate 16Bevacizumab 16Tacrolimus 14Antilymphocyte Serum 14Nivolumab 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Recurrence × Ado-Trastuzumab Emtansine × Clear all
NCT00991562 2014-11-21

IMGN901 in Combination With Lenalidomide and Dexamethasone

ImmunoGen, Inc.

Phase 1 Completed
50 enrolled
Plasma cell

Multiple Myeloma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡